Myriad's BRCA gene patents ruled invalid by US court
This article was originally published in Scrip
A US federal judge has invalidated some of Myriad Genetics’ patent claims on two key genes involved in hereditary breast and ovarian cancer – BRCA1 and BRCA2 – in a controversial ruling that could have profound effects on gene patent law and the biotech industry's intellectual property foundation if it is upheld on appeal.
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.